Eugia recalls medroxyprogesterone acetate injectable for CGMP deviations
Eugia US LLC recalls 150mg per mL medroxyprogesterone acetate injectable vials manufactured in India due to CGMP deviations. This is a prescription-only product for medical use.
Recall notice
CGMP Deviations
Contact the company
What happened, in plain English
Eugia US LLC is recalling 150mg per mL medroxyprogesterone acetate injectable vials made in India because of manufacturing quality control issues. This product is prescription-only and used for medical treatments. Read more at govinfonow.com/recall/32356-eugia-recalls-medroxyprogesterone-acetate-injectable-for-cgmp-deviations.
Source Summary by GovInfoNow · govinfonow.com/recall/32356-eugia-recalls-medroxyprogesterone-acetate-injectable-for-cgmp-deviations · Updated August 17, 2026 · FDA enforcement record: FDA #D-0185-2025
Cite this page
“Eugia recalls medroxyprogesterone acetate injectable for CGMP deviations.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32356-eugia-recalls-medroxyprogesterone-acetate-injectable-for-cgmp-deviations. Based on FDA recall #D-0185-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0185-2025%22&limit=1).
Why it’s dangerous
CGMP deviations refer to failures in the manufacturing process that could affect product safety and quality. This means the medication might not meet the required standards for medical use, though the exact risk is not specified in the recall notice.
Who’s affected
Prescription patients using this specific injectable medication are affected. Healthcare providers who dispensed the product may also be impacted.
How to tell if you have this one
Look for vials labeled 'medroxyPROGESTERone Acetate Injectable Suspension, USP, 150 mg per mL' with NDC 55150-329-01, manufactured in India, and lot number 1MP24069 (expires 08/2026).
- Brand
Eugia- Category
Drug
What to do — step by step
Check Product Details
Verify the product label matches the description: 150mg per mL, NDC 55150-329-01, manufactured in India, lot 1MP24069, expiring 08/2026.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 28 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0185-2025 (December 18, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0185-2025 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.